1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoserine

Term ID

CHEBI:79103

Synonyms

1-palmitoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoserine
O-{[(2R)-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyloxy]-3-(hexadecanoyloxy)propoxy](hydroxy)phosphoryl}-L-serine
Phosphatidylserine(16:0/22:6)
Phosphatidylserine(16:0/22:6n3)
Phosphatidylserine(16:0/22:6w3)
Phosphatidylserine(38:6)
PS(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
PS(16:0/22:6)
PS(16:0/22:6n3)
PS(16:0/22:6w3)
PS(38:6)
PSer(16:0/22:6)
PSer(16:0/22:6n3)
PSer(16:0/22:6w3)
PSer(38:6)

Definition

References

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from 1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoserine

Phenotype where environments contain 1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoserine

Phenotype modified by environments containing 1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoserine

Phenotype affecting 1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoserine

Human Disease Model